ArticleFrontiers in immunology2025
Clinical outcomes and early- prognostic biomarkers of primary biliary cholangitis with ductopenia.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Novel Mechanistic Insights into Primary Biliary Cholangitis: From Pathogenesis to Mesenchymal Stem Cell-Mediated Repair.Biomedicines · 2026Review
- Dynamic AFP-Defined Disease State Transitions in Hospitalized Patients with Hepatocellular Carcinoma Using the Multi-State Markov Model: A Retrospective Cohort Study.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ductopenia drives biochemical failure and histological progression in primary biliary cholangitis (PBC), influencing its course and prognosis, but its prevalence, features, and prognosis remain unclear. This study aimed to characterize ductopenia in PBC and identify early predictive biomarkers. Methods: From August 2013 to April 2025, 518 of the biopsy-proven PBC patients were enrolled, analyzed for demographics, pathology, and clinical features, and grouped by ductopenia presence. 201 patients were followed until June 15, 2025, with liver-related adverse events (including TIPS, splenectomy with portosystemic shunt or portoazygous devascularization, liver failure, death, or liver transplantation) as endpoints. Kaplan-Meier and Cox regression assessed prognosis. Results: The overall proportion of patients with PBC and ductopenia was 56.76% (294/518), Notably, ductopenia was present in 24.83% (74/298) of patients with early-stage disease. Compared with the group without ductopenia, the ductopenia group showed significantly higher levels of cholestasis indicators (such as TBIL, ALP, GGT, and TBA) and autoantibodies (ANA, AMA anti-gp210), but significantly lower levels of liver synthetic function indicators (such as ALB and cholinesterase) and blood components (RBC, PLT, and HGB) (all Conclusions: Ductopenia is relatively common in patients with PBC, and its prevalence significantly increases with disease progression. Ductopenia was an independent risk factor for the occurrence of liver-related adverse events in patients with PBC. ANA(≥1:1000), TBIL, GGT, and ALB are early predictive biomarkers for ductopenia in patients with PBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.